News & Events
The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.
November 20, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that a narrative review of…
READ MORE
SEATTLE, October 17, 2019 — Impel NeuroPharma today announced that Diane Wilfong has been appointed to the Company’s board of directors. Diane brings 30 years of financial and operations experience in large, multinational companies, including most currently serving as Senior…
READ MORE
SEATTLE, September 5, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it will present…
READ MORE
SEATTLE, September 3, 2019 — Impel NeuroPharma today announced the last patient has been enrolled in “STOP-301” (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute…
READ MORE
SEATTLE, July 10, 2019 — Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DHE) Delivered by Impel’s POD® Device, Support Bioavailability, Safety and Tolerability Profile of INP104 for Acute Migraine. Company’s Phase 3 Clinical…
READ MORE
SEATTLE, June 26, 2019 — Impel NeuroPharma today announced the appointment of John Leaman, M.D., as the Company’s Chief Financial Officer.
READ MORE
SEATTLE, May 17, 2019 — Phase 1 Data Support Selection of Company’s Proprietary Formulation of Investigational Nasal Olanzapine, INP105, Currently Being Evaluated for Acute Agitation in Bipolar 1 and Schizophrenia
READ MORE
SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019…
READ MORE
SEATTLE, February 19, 2019 — Significant Leadership Experience in CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization. Impel NeuroPharma today announced that Jennifer L. Berman has joined the Company as the Vice President of Marketing.
READ MORE
SEATTLE, Jan. 6, 2019 /PRNewswire/ — Data Demonstrated Nasal Delivery of INP105 (POD-olanzapine) Achieved Peak Olanzapine Plasma Levels Twice as Fast as Intramuscular Injection, Ten-Times Faster than Orally-Disintegrating Tablets Study Showed a Safety and Tolerability Profile Consistent with Currently Marketed…
READ MORE